Recently Featured

Neurogene Hires New CCO as It Eyes Commercial Future for Its Rett Gene Therapy

April 24, 2026
Neurogene has appointed a new Chief Commercial Officer (CCO) as it transitions from a clinical-stage biotech to a commercial biopharmaceutical company, focusing on its lead gene therapy for Rett syndrome. This strategic hire underscores the company’s commitment to building a robust commercial infrastructure ahead of potential market entry. The appointment of an industry veteran to…

Trump Orders FDA to Fast-Track Reviews of Psychedelic Drugs Following Podcaster Lobbying

April 24, 2026
President Donald Trump has mandated the FDA to prioritize the review process for psychedelic drugs, a significant shift aimed at enhancing access to treatments for serious mental health conditions. This directive follows substantial lobbying efforts from influential figures in the media, notably a prominent podcaster advocating for the therapeutic potential of these substances. This move…

Bayer falls short in bid to block J&J’s survival claims in prostate cancer clash

April 24, 2026
In a significant legal setback for Bayer, a U.S. federal judge in Manhattan has ruled against the company’s attempt to block Johnson & Johnson’s survival claims related to a key prostate cancer drug. This decision allows J&J to proceed with its assertions, which may impact Bayer’s competitive positioning in the oncology market. The ruling underscores…

Biovac secures $108M financing to establish Africa’s first fully integrated vaccine plant

April 24, 2026
Biovac has secured a $108.3 million financing package that will enable the South African pharmaceutical company to construct Africa’s first fully integrated, end-to-end vaccine production facility. This significant investment marks a pivotal moment in the continent’s biopharmaceutical landscape, addressing the urgent need for local vaccine manufacturing capabilities, especially in the wake of global health challenges…

Ongoing Cases